Idebenone prevents human optic nerve head astrocytes from oxidative stress, apoptosis, and senescence by stabilizing BAX/Bcl-2 ratio

Journal of Glaucoma

Volumn 22, Issue 5, 2013, Pages 404-412

  Kernt, Marcus ^a   Arend, Nicole ^a   Buerger, Alexandra ^a   Mann, Thomas ^a   Haritoglou, Christos ^a   Ulbig, Michael W ^a   Kampik, Anselm ^a   Hirneiss, Christoph ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Antioxidants; Apoptosis; Astrocytes; Coenzyme Q10; Glaucoma; Idebenone; Optic nerve head; Oxidative stress; Senescence

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; BETA GALACTOSIDASE; DNA; HISTONE; HYDROGEN PEROXIDE; IDEBENONE; MESSENGER RNA; PROTEIN BAX; PROTEIN BCL 2; REACTIVE OXYGEN METABOLITE;

APOPTOSIS; ARTICLE; ASTROCYTE; CELL PROTECTION; CELL VIABILITY; CONTROLLED STUDY; DNA FRAGMENTATION; HUMAN; HUMAN CELL; OPTIC NERVE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SENESCENCE; WESTERN BLOTTING;

ADULT; AGED; ANTIOXIDANTS; APOPTOSIS; ASTROCYTES; BCL-2-ASSOCIATED X PROTEIN; BETA-GALACTOSIDASE; BLOTTING, WESTERN; CELL AGING; CELL SURVIVAL; CELLS, CULTURED; HUMANS; HYDROGEN PEROXIDE; MIDDLE AGED; OPTIC DISK; OXIDATIVE STRESS; PROTO-ONCOGENE PROTEINS C-BCL-2; REACTIVE OXYGEN SPECIES; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; TISSUE DONORS; UBIQUINONE;

EID: 84879173613     PISSN: 10570829     EISSN: 1536481X     Source Type: Journal    
DOI: 10.1097/IJG.0b013e31824caf90     Document Type: Article

References (58)

1. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006; 90:262-267.
2. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701-713; discussion 829-830.
3. Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120:1268-1279.
4. Leske MC, Heijl A, Hussein M, et al. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol. 2003;121:48-56.
5. Leske MC, Heijl A, Hyman L, et al. Predictors of long-term progression in the early manifest glaucoma trial. Ophthalmology. 2007;114:1965-1972.
6. Kerrigan LA, Zack DJ, Quigley HA, et al. TUNEL-positive ganglion cells in human primary open-angle glaucoma. Arch Ophthalmol. 1997;115:1031-1035.
7. Libby RT, Li Y, Savinova OV, et al. Susceptibility to neurodegeneration in a glaucoma is modified by Bax gene dosage. PLoS Genet. 2005;1:17-26.
8. Tatton NA, Tezel G, Insolia SA, et al. In situ detection of apoptosis in normal pressure glaucoma. A preliminary examination. Surv Ophthalmol. 2001;45(suppl 3):S268-S272; discussion S73-S76.
9. Tatton WG, Chalmers-Redman RM, Tatton NA. Apoptosis and anti-apoptosis signalling in glaucomatous retinopathy. Eur J Ophthalmol. 2001;11(suppl 2):S12-S22.
10. Kernt M, Neubauer AS, Ulbig MW, et al. In vitro safety of intravitreal moxifloxacin for endophthalmitis treatment. J Cataract Refract Surg. 2008;34:480-488.
11. Kernt M, Liegl RG, Rueping J, et al. Sorafenib protects human optic nerve head astrocytes from light-induced over-expression of vascular endothelial growth factor, platelet-derived growth factor, and placenta growth factor. Growth Factors. 2010;28:211-220.
12. Kernt M, Kampik A. Intraocular caspofungin: in vitro safety profile for human ocular cells. Mycoses. 2011;54:110-121.
13. Prasanna G, Krishnamoorthy R, Yorio T. Endothelin astrocytes and glaucoma. Exp Eye Res. 2011;93:170-177.
14. Hernandez MR, Miao H, Lukas T. Astrocytes in glaucoma-tous optic neuropathy. Prog Brain Res. 2008;173:353-373.
15. Luo C, Yang X, Kain AD, et al. Glaucomatous tissue stress and the regulation of immune response through glial Toll-like receptor signaling. Invest Ophthalmol Vis Sci. 2010;51: 5697-5707.
16. Johnson EC, Morrison JC. Friend or foe? Resolving the impact of glial responses in glaucoma. J Glaucoma. 2009;18: 341-353.
17. Ganesh BS, Chintala SK. Inhibition of reactive gliosis attenuates excitotoxicity-mediated death of retinal ganglion cells. PLoS One. 2011;6:e18305.
18. Galpern WR, Cudkowicz ME. Coenzyme Q treatment of neurodegenerative diseases of aging. Mitochondrion. 2007; 7(suppl):S146-S153.
19. Imagawa M, Naruse S, Tsuji S, et al. Coenzyme Q10, iron, and vitamin B6 in genetically-confirmed Alzheimer's disease. Lancet. 1992;340:671.
20. Ferreira SM, Lerner SF, Brunzini R, et al. Oxidative stress markers in aqueous humor of glaucoma patients. Am J Ophthalmol. 2004;137:62-69.
21. Levin LA, Clark JA, Johns LK. Effect of lipid peroxidation inhibition on retinal ganglion cell death. Invest Ophthalmol Vis Sci. 1996;37:2744-2749.
22. Sacca SC, Pascotto A, Camicione P, et al. Oxidative DNA damage in the human trabecular meshwork: clinical correlation in patients with primary open-angle glaucoma. Arch Ophthal-mol. 2005;123:458-463.
23. Hollyfield JG, Bonilha VL, Rayborn ME, et al. Oxidative damage-induced inflammation initiates age-related macular degeneration. Nat Med. 2008;14:194-198.
24. Kong GY, Van Bergen NJ, Trounce IA, et al. Mitochondrial dysfunction and glaucoma. J Glaucoma. 2009;18:93-100.
25. Kumar DM, Agarwal N. Oxidative stress in glaucoma: a burden of evidence. J Glaucoma. 2007;16:334-343.
26. Liu Q, Ju WK, Crowston JG, et al. Oxidative stress is an early event in hydrostatic pressure induced retinal ganglion cell damage. Invest Ophthalmol Vis Sci. 2007;48:4580-4589.
27. McDaniel DH, Neudecker BA, DiNardo JC, et al. Idebenone: a new antioxidant-part I. Relative assessment of oxidative stress protection capacity compared to commonly known antioxidants. J Cosmet Dermatol. 2005;4:10-17.
28. Meier T, Buyse G. Idebenone: an emerging therapy for Friedreich ataxia. J Neurol. 2009;256(suppl 1):25-30.
29. Mestre T, Ferreira J, Coelho MM, et al. Therapeutic interventions for disease progression in Huntington's disease. Cochrane Database Syst Rev. 2009;3:CD006455.
30. Voronkova KV, Meleshkov MN. Use of Noben (idebenone) in the treatment of dementia and memory impairments without dementia. Neurosci Behav Physiol. 2009;39:501-506.
31. Klopstock T, Yu-Wai-Man P, Dimitriadis K, et al. A randomized placebo-controlled trial of idebenone in Leber's hereditary optic neuropathy. Brain. 2011;134(pt 9): 2677-2686.
32. Neufeld AH, Liu B. Glaucomatous optic neuropathy: when glia misbehave. Neuroscientist. 2003;9:485-495.
33. Villalba JM, Parrado C, Santos-Gonzalez M, et al. Therapeutic use of coenzyme Q10 and coenzyme Q10-related compounds and formulations. Expert Opin Investig Drugs. 2010;19: 535-554.
34. Deigner HP, Haberkorn U, Kinscherf R. Apoptosis modulators in the therapy of neurodegenerative diseases. Expert Opin Investig Drugs. 2000;9:747-764.
35. Gil J, Almeida S, Oliveira CR, et al. Cytosolic and mitochondrial ROS in staurosporine-induced retinal cell apoptosis. Free Radic Biol Med. 2003;35:1500-1514.
36. Kernt M, Neubauer AS, Eibl KH, et al. Minocycline is cytoprotective in human trabecular meshwork cells and optic nerve head astrocytes by increasing expression of XIAP, survivin, and Bcl-2. Clin Ophthalmol. 2010;4:591-604.
37. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65:55-63.
38. Kernt M, Neubauer AS, Liegl RG, et al. Sorafenib prevents human retinal pigment epithelium cells from light-induced overexpression of VEGF, PDGF and PlGF. Br J Ophthalmol. 2010;94:1533-1539.
39. Kernt M, Hirneiss C, Neubauer AS, et al. Coenzyme Q10 prevents human lens epithelial cells from light-induced apoptotic cell death by reducing oxidative stress and stabilizing BAX/Bcl-2 ratio. Acta Ophthalmol. 2010;88:e78-e86.
40. Dimri GP, Lee X, Basile G, et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci USA. 1995;92:9363-9367.
41. Nishikawa T, Edelstein D, Du XL, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature. 2000;404:787-790.
42. Kernt M, Hirneiss C, Wolf A, et al. Indocyanine green increases light-induced oxidative stress, senescence, and matrix metalloproteinases 1 and 3 in human RPE cells. Acta Ophthalmol. 2012;90:571-579.
43. Kernt M, Neubauer AS, Liegl R, et al. Cytoprotective effects of a blue light-filtering intraocular lens on human retinal pigment epithelium by reducing phototoxic effects on vascular endothelial growth factor-alpha, Bax, and Bcl-2 expression. J Cataract Refract Surg. 2009;35:354-362.
44. Moreno MC, Campanelli J, Sande P, et al. Retinal oxidative stress induced by high intraocular pressure. Free Radic Biol Med. 2004;37:803-812.
45. Temple MD, Perrone GG, Dawes IW. Complex cellular responses to reactive oxygen species. Trends Cell Biol. 2005; 15:319-326.
46. Canakci CF, Cicek Y, Canakci V. Reactive oxygen species and human inflammatory periodontal diseases. Biochemistry (Mosc). 2005;70:619-628.
47. Jarrett SG, Lin H, Godley BF, et al. Mitochondrial DNA damage and its potential role in retinal degeneration. Prog Retin Eye Res. 2008;27:596-607.
48. Zamzami N, Kroemer G. The mitochondrion in apoptosis: how Pandora's box opens. Nat Rev Mol Cell Biol. 2001;2: 67-71.
49. Martinou JC, Green DR. Breaking the mitochondrial barrier. Nat Rev Mol Cell Biol. 2001;2:63-67.
50. Chang MY, Sun W, Ochiai W, et al. Bcl-XL/Bax proteins direct the fate of embryonic cortical precursor cells. Mol Cell Biol. 2007;27:4293-4305.
51. Liang YG, Jorgensen AG, Kaestel CG, et al. Bcl-2, Bax, and c-Fos expression correlates to RPE cell apoptosis induced by UV-light and daunorubicin. Curr Eye Res. 2000;20:25-34.
52. Lindsten T, Zong WX, Thompson CB. Defining the role of the Bcl-2 family of proteins in the nervous system. Neuroscientist. 2005;11:10-15.
53. Kluck RM, Esposti MD, Perkins G, et al. The pro-apoptotic proteins, Bid and Bax, cause a limited permeabilization of the mitochondrial outer membrane that is enhanced by cytosol. J Cell Biol. 1999;147:809-822.
54. Esposti MD, Hatzinisiriou I, McLennan H, et al. Bcl-2 and mitochondrial oxygen radicals. New approaches with reactive oxygen species-sensitive probes. J Biol Chem. 1999;274: 29831-29837.
55. Okamoto K, Matsumoto M, Watanabe M, et al. Effects of 6-(omega-substituted alkyl)-2, 3-dimethoxy-5-methyl-1, 4-ben-zoquinones and related compounds on mitochondrial succinate and reduced nicotinamide adenine dinucleotide oxidase systems. Chem Pharm Bull (Tokyo). 1985;33: 3745-3755.
56. Bergamasco B, Scarzella L, La Commare P. Idebenone, a new drug in the treatment of cognitive impairment in patients with dementia of the Alzheimer type. Funct Neurol. 1994;9: 161-168.
57. Sramek JJ, Cutler NR. Recent developments in the drug treatment of Alzheimer's disease. Drugs Aging. 1999;14: 359-373.
58. Crane FL. Biochemical functions of coenzyme Q10. J Am Coll Nutr. 2001;20:591-598.